The FDA plans to reduce the number of required pivotal trials in Phase 3 clinical studies from two to one, aiming to streamline drug development. While this may benefit smaller biotech companies, the impact will vary by disease, as some conditions may still necessitate more trials to ensure safety and efficacy.

Until Labs is pioneering controlled-rate freezers and cryoprotectants to achieve reversible cryopreservation, allowing tissues to enter a glassy state rather than freezing. This technology aims to extend the viability of organs for transplantation, potentially transforming the landscape of organ donation and medical treatment for end-stage organ diseases.